FIELD: pharmacology.
SUBSTANCE: invention is an oral bio-available non-aqueous liquid composition containing at least 7 wt % of propylene glycol in the total composition weight, a cardiotonic means, or angiotensin-converting enzyme inhibitor, or combination of cardiotonic means and angiotensin-converting enzyme inhibitor. Invention discloses a method for obtaining the composition described above, by mixing at least 7 wt % of propylene glycol by the total composition weight with a cardiotonic means, or angiotensin-converting enzyme inhibitor, or a combination of cardiotonic means with angiotensin-converting enzyme inhibitor.
EFFECT: treatment of heart disease and hypertension.
34 cl, 11 dwg, 17 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING DOGS WITH DILATED CARDIOMYOPATHY COMPLICATED BY CONGESTIVE CARDIAC FAILURE | 2020 |
|
RU2762989C1 |
| METHOD FOR TREATING DOGS WITH MITRAL VALVE ENDOCARDIOSIS | 2020 |
|
RU2745653C1 |
| TELMISARTAN FOR TREATING CHRONIC KIDNEY DISEASE IN DOGS | 2020 |
|
RU2832966C2 |
| TELMISARTAN FOR TREATING HYPERTENSION IN DOGS | 2020 |
|
RU2830555C2 |
| COMBINATION OF AT LEAST TWO COMPOUNDS CHOSEN FROM GROUPS AT-RECEPTOR ANTAGONISTS OR INHIBITORS OF ACE (ANGIOTENSIN-CONVERTING ENZYME) OR INHIBITORS OF HMG-COA-REDUCTASE (BETA-HYDROXY-BETA-METHYLGLUTARYL-COENZYME-A-REDUCTASE) | 2001 |
|
RU2298418C2 |
| METHOD FOR DECREASING A LETHALITY RATE AS A RESULT OF A STATIC HEART FAILURE BY USING CARVEDILOL | 1996 |
|
RU2197242C2 |
| RENIN INHIBITOR-CONTAINING SYNERGETIC COMPOSITIONS DESIGNATED FOR TREATMENT OF CARDIOVASCULAR DISEASE | 2001 |
|
RU2310443C2 |
| ANGIOTENSIN CONVERTING ENZYME INHIBITORS FOR TREATING OPTIC NEUROPATHY OR CONGENITAL OPTIC ATROPHY | 2013 |
|
RU2658461C2 |
| APPLICATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR TREATMENT OF ACUTE MYOCARDIAL INFARCTION | 2006 |
|
RU2345790C2 |
| PHARMACEUTICAL PREPARATIONS AND THEIR APPLICATION FOR PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE | 2005 |
|
RU2378018C2 |
